💊 The Drug That Helped Brain Implants, and What It Taught Us

🩺 A few years ago, my lab asked a simple question: if oligodendrocyte dysfunction is contributing to BCI failure, can we fix it with a drug?

We chose Clemastine, an antihistamine that has been shown in other contexts to promote oligodendrocyte differentiation and myelination. It is FDA-approved, orally administered, crosses the blood-brain barrier, and has a known safety profile. It targets signaling pathways specific to oligodendrocytes through muscarinic receptors. If you wanted to test the oligodendrocyte hypothesis in a living brain, it was a reasonable tool.

📈 The results were striking. In mice receiving Clemastine starting one week before electrode implantation, myelin levels near the electrode were roughly 180% of controls. Chronic recording stability improved by approximately 140%. Critically, inhibitory neuronal activity, the first thing to degrade in our recordings without intervention, was substantially better preserved.

🧫 Demonstrating that a drug targeting oligodendrocytes improves chronic BCI recording requires a living brain, a functioning immune system, intact vasculature, and months of electrophysiology, conditions no current non-animal model (NAMs) can provide.

⚠️ I want to be careful about how I frame this. Clemastine is not a BCI treatment. These are rodent experiments, and translation from rodent to human is never guaranteed. The appropriate response to these findings is not to start taking Clemastine before a BCI surgery. It is to take the oligodendrocyte hypothesis seriously as a target, fund research to understand the mechanism more deeply, and explore whether this or related compounds have a role in improving device longevity in humans.

🔎 But the experiment taught us something beyond the drug effect. The fact that a pharmacological intervention targeting a non-neuronal cell type, not neurons, not the electrode surface, not the biomaterial coating, could meaningfully change recording performance is itself important. It tells us that the failure we observe in chronic BCI recordings is not purely a materials problem or a surgical problem. It is partly a cellular biology problem. And cellular biology problems have biological solutions.

👨‍👩‍👧‍👦 The field has spent enormous resources making better electrodes. We may also need to make better biological neighborhoods for those electrodes to live in.

Clemastine: https://lnkd.in/eyNPriA9
Fus in Oligo: https://lnkd.in/eFErQ2i9

#Neuroscience #DrugDiscovery #Neurotechnology #BrainComputerInterface #Bioengineering